| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
KG5 manufacturers
- KG5
-
- $29.00
-
2026-07-27
- CAS:877874-85-6
- Purity: 98.32%
- Supply Ability: 10g
|
| Product Name: | KG5 | | Synonyms: | KG5;2-methylsulfanyl-6-[4-[3-[3-(trifluoromethyl)anilino]-1H-1,2,4-triazol-5-yl]phenoxy]pyrimidin-4-amine;2-(Methylthio)-6-[4-[5-[[3-(trifluoromethyl)phenyl]amino]-1H-1,2,4-triazol-3-yl]phenoxy]-4-pyrimidinamine;4-Pyrimidinamine, 2-(methylthio)-6-[4-[5-[[3-(trifluoromethyl)phenyl]amino]-1H-1,2,4-triazol-3-yl]phenoxy]-;B-Raf,antiangiogenic,KIT,c-Kit,KG5,CD135,Raf kinases,Raf,PDGFR,Cluster of differentiation antigen 135,Platelet-derived growth factor receptor,Fms like tyrosine kinase 3,metastasis,c-Raf,FLT3,PDGFRβ,inhibit,anticancer,phosphorylation,SCFR,Inhibitor,KG 5,CD117,KG-5;2-(Methylthio)-6-(4-(5-((3-(trifluoromethyl)phenyl)amino)-4H-1,2,4-triazol-3-yl)phenoxy)pyrimidin-4-amine;KG5, 10 mM in DMSO | | CAS: | 877874-85-6 | | MF: | C20H16F3N7OS | | MW: | 459.45 | | EINECS: | | | Product Categories: | | | Mol File: | 877874-85-6.mol |  |
| Boiling point | 654.0±65.0 °C(Predicted) | | density | 1.54±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | pka | 9.54±0.40(Predicted) | | color | White to off-white | | SMILES | NC1=CC(OC2=CC=C(C3=NN=C(NC4=CC(C(F)(F)F)=CC=C4)N3)C=C2)=NC(SC)=N1 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| Uses | KG 5 is orally active drug that stabilizes inactive state of PDGFRβ/B-RAF and inhibits tumor angiogenesis. | | in vivo | KG5 (Compound 6; 100 mg/kg; oral administration; daily; for 26 days) treatment prevents tumor growth in an orthotopic renal cell carcinoma model[1].
KG5 (Compound 6; 50 mg/kg; i.p.; twice daily) treatment completely blocks angiogenesis relative to vehicle control in mice (injected with Matrigel containing bFGF). Pharmacokinetic analysis of the dose and formulation of KG5 used indicated a Cmax of 3.6 μg/mL, T1/2 of 11.5 h, and an area under the concentration time curve (AUC0-12h) of 14.7 μgh/mL[1].
KG5 (Compound 6; 1 μM) disrupts a late step in angiogenesis during zebrafish embryogenesis[1]. | Animal Model: | Male Nu/Nu mice injected with SN12C-RFP cells[1] | | Dosage: | 100 mg/kg | | Administration: | Oral administration; daily; for 26 days | | Result: | Prevented tumor growth in an orthotopic renal cell carcinoma model.
|
| | IC 50 | B-Raf; PDGFRβ: 520 nM (Kd); FLT3: 52 nM (Kd); KIT: 170 nM (Kd); PDGFRα: 300 nM (Kd); c-Raf | | storage | Store at -20°C |
| | KG5 Preparation Products And Raw materials |
|